Neprilysin inhibition: A brief review of past pharmacological strategies for heart failure treatment and future directions.
Heart failure (HF) is a manifestation of aberrant vascular responses and remains a public health concern with a worldwide prevalence of around 23 million and a 5-year mortality numerically equivalent to many cancers. Over the last two decades, mortality from HF reached a plateau with current pharmaceutical agents and mechanical cardiac support. In the last several years, various "novel" pharmaceutical agents have been tested in clinical trials and ultimately met with disappointment, showing only incremental benefit in the treatment of HF. Designing a HF drug with enhanced efficacy over existing agents seemed like a Sisyphean task. Yet again, pharmaceutical chemists have demonstrated their prowess in lateral thinking by developing a vasoactive agent which is a co-crystallized compound of valsartan and sacubitril in a one-to-one molar ratio; the former molecule belongs to a family of agents that are the current standard of care for HF and the latter molecule is a novel agent which inhibits neprilysin - a neutral endopeptidase found in human plasma which alters neurohumoral responses. In July of 2015, a drug which is a combination of valsartan and sacubitril was formally licensed by the United States Food and Drug Administration for the treatment of HF. This review describes the evolution of HF medications focusing on rational drug design with the first HF medication, the beta-adrenergic receptor antagonist. We then discuss the biochemical and physiological properties of sacubitril/valsartan which likely lead to its dramatic ability to ameliorate HF mortality.
Erik H
EH
Howell
Department of Medicine, Division of Cardiology, and Aab Institute for Cardiovascular Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States. scott_cameron@urmc.rochester.edu.
Scott J
SJ
Cameron
D000613:Aminobutyrates / Q000627:therapeutic use*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use; D001713:Biphenyl Compounds; D004338:Drug Combinations; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D015260:Neprilysin / Q000037:antagonists & inhibitors*; D012084:Renin-Angiotensin System / Q000235:genetics*; D013777:Tetrazoles / Q000627:therapeutic use*; D000068756:Valsartan / Q000627:therapeutic use*
D000613:Aminobutyrates; D047228:Angiotensin II Type 1 Receptor Blockers; D057911:Angiotensin Receptor Antagonists; D001713:Biphenyl Compounds; D004338:Drug Combinations; D013777:Tetrazoles; D000068756:Valsartan; D015260:Neprilysin; C549068:sacubitril and valsartan sodium hydrate drug combination
LCZ696; cardiomyopathy; heart failure; neprilysin; sacubitril; valsartan endopeptidase
Eur Heart J. 1995 Jun;16(6):741-51
7588917
Postgrad Med J. 1986;62 Suppl 1:23-7
3534860
J Card Fail. 2014 Dec;20(12):973-83
25175694
N Engl J Med. 2011 Jul 7;365(1):32-43
21732835
J Clin Pharmacol. 2010 Apr;50(4):401-14
19934029
Lancet. 1989 Sep 9;2(8663):591-3
2570286
Curr Pharm Des. 2012;18(2):186-91
22229578
J Nucl Med. 2004 Jul;45(7):1108-13
15235055
Int J Cardiol. 2004 Dec;97(3):345-8
15561317
N Engl J Med. 1987 Jun 4;316(23):1429-35
2883575
Heart Fail Rev. 2015 Nov;20(6):643-53
26404098
Circulation. 1991 Jun;83(6):1849-65
1828192
Lancet. 2012 Oct 20;380(9851):1387-95
22932717
Cardiovasc Drugs Ther. 2002 May;16(3):209-14
12374898
Clin Pharmacol Ther. 1999 Apr;65(4):448-59
10223783
Ann Noninvasive Electrocardiol. 2005 Oct;10(4 Suppl):34-43
16274414
Am Heart J. 2008 Jan;155(1):9-18
18082483
Circulation. 2006 Apr 25;113(16):1966-73
16618817
N Engl J Med. 2005 Jan 20;352(3):225-37
15659722
N Engl J Med. 2003 Apr 3;348(14):1309-21
12668699
N Engl J Med. 2014 Dec 18;371(25):2435
25517716
J Am Coll Cardiol. 2015 Feb 3;65(4):378-88
25634838
J Pharmacol Sci. 2006;100(5):323-37
16612046
Circulation. 2015 Jan 6;131(1):54-61
25403646
J Mol Cell Cardiol. 2013 Dec;65:9-18
24095877
Br J Anaesth. 2012 Mar;108(3):384-94
22290457
Clin Ther. 2015 Oct 1;37(10):2199-205
26386501
Lancet. 2003 Sep 6;362(9386):759-66
13678868
N Engl J Med. 1992 Sep 3;327(10):669-77
1386652
Sci Rep. 2016 Jul 13;6:29760
27407064
Clin Med Insights Cardiol. 2015 Jun 25;9(Suppl 1):101-4
26157338
J Med Chem. 1978 Jan;21(1):68-72
22756
Heart Fail Clin. 2008 Jan;4(1):87-97
18313627
Lancet. 1993 Oct 2;342(8875):821-8
8104270
N Engl J Med. 2014 Sep 11;371(11):989-91
25184412
N Engl J Med. 2014 Sep 11;371(11):993-1004
25176015
Heart Fail Rev. 2015 Nov;20(6):731-49
26423909
JAMA. 2016 Jan 5;315(1):25-6
26641736
N Engl J Med. 1999 Sep 2;341(10):709-17
10471456
Clin Cardiol. 2008 Sep;31(9):407-12
18781599
Nat Rev Drug Discov. 2008 May;7(5):399-410
18340340
Lancet. 1999 Jan 2;353(9146):9-13
10023943
J Card Fail. 2015 Sep;21(9):741-50
26209000
Circulation. 2002 Aug 20;106(8):920-6
12186794
N Engl J Med. 2014 Apr 10;370(15):1383-92
24716680
Circulation. 2004 Aug 24;110(8):975-81
15313942
Hypertension. 2011 Feb;57(2):e4-5
21149824
JACC Cardiovasc Imaging. 2015 Sep;8(9):1071-93
26381769
Eur J Clin Pharmacol. 2007 Jul;63(7):699-702
17479256
Circ Heart Fail. 2011 Jan;4(1):44-52
21075869
J Med Chem. 1995 May 12;38(10):1689-700
7752193
J Am Coll Cardiol. 2009 Nov 3;54(19):1747-62
19874988
Cardiovasc Res. 2014 Jul 15;103(2):268-80
24692173
J Am Coll Cardiol. 1999 Jul;34(1):155-62
10400005
Eur Heart J. 2015 Apr 14;36(15):902-5
25636748
Lancet. 1997 Mar 15;349(9054):747-52
9074572
Lancet. 1999 Jun 12;353(9169):2001-7
10376614
Curr Alzheimer Res. 2015;12(1):32-46
25523424
Eur Heart J. 2015 Aug 7;36(30):1974-82b
25975657
Prog Cardiovasc Dis. 2005 Mar-Apr;47(5):320-32
16003647
Lancet. 1964 May 16;1(7342):1080-1
14132613
Eur J Heart Fail. 2015 Oct;17(10):1075-83
26511146
Circ Res. 2004 Dec 10;95(12 ):1167-73
15539634
N Engl J Med. 2001 May 31;344(22):1651-8
11386263
JACC Heart Fail. 2014 Dec;2(6):663-70
25306450
Cardiovasc Drugs Ther. 2001 Jan;15(1):79-87
11504167
Lancet. 2000 May 6;355(9215):1582-7
10821361
N Engl J Med. 1991 Aug 1;325(5):293-302
2057034
Am Heart J. 1991 Jun;121(6 Pt 1):1852-3
2035416
Trends Cardiovasc Med. 2016 Feb;26(2):137-46
26051208
Am J Hypertens. 2003 Nov;16(11 Pt 1):931-7
14573331
Lancet. 2010 Sep 11;376(9744):886-94
20801495
Nat Rev Cardiol. 2015 Feb;12(2):73-5
25560375
Mayo Clin Proc. 2015 Sep;90(9):1247-61
26189443
Br J Clin Pharmacol. 2004 Jan;57(1):27-36
14678337
Circulation. 2015 Feb 10;131(6):550-9
25552356
Clin Cardiol. 2008 Apr;31(4):153-8
18404673